Prothena Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Gene Kinney
Chief executive officer
US$5.9m
Total compensation
| CEO salary percentage | 11.75% |
| CEO tenure | 10yrs |
| CEO ownership | 0.3% |
| Management average tenure | 7.1yrs |
| Board average tenure | 13.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$44m |
| Mar 31 2026 | n/a | n/a | -US$151m |
| Dec 31 2025 | US$6m | US$693k | -US$244m |
| Sep 30 2025 | n/a | n/a | -US$280m |
| Jun 30 2025 | n/a | n/a | -US$303m |
| Mar 31 2025 | n/a | n/a | -US$110m |
| Dec 31 2024 | US$7m | US$654k | -US$122m |
| Sep 30 2024 | n/a | n/a | -US$132m |
| Jun 30 2024 | n/a | n/a | -US$51m |
| Mar 31 2024 | n/a | n/a | -US$172m |
| Dec 31 2023 | US$7m | US$631k | -US$147m |
| Sep 30 2023 | n/a | n/a | -US$73m |
| Jun 30 2023 | n/a | n/a | -US$141m |
| Mar 31 2023 | n/a | n/a | -US$128m |
| Dec 31 2022 | US$7m | US$601k | -US$117m |
| Sep 30 2022 | n/a | n/a | -US$156m |
| Jun 30 2022 | n/a | n/a | -US$1m |
| Mar 31 2022 | n/a | n/a | US$67m |
| Dec 31 2021 | US$5m | US$573k | US$67m |
| Sep 30 2021 | n/a | n/a | US$69m |
| Jun 30 2021 | n/a | n/a | -US$70m |
| Mar 31 2021 | n/a | n/a | -US$124m |
| Dec 31 2020 | US$3m | US$554k | -US$111m |
| Sep 30 2020 | n/a | n/a | -US$102m |
| Jun 30 2020 | n/a | n/a | -US$91m |
| Mar 31 2020 | n/a | n/a | -US$80m |
| Dec 31 2019 | US$3m | US$538k | -US$78m |
Compensation vs Market: Gene's total compensation ($USD5.90M) is above average for companies of similar size in the German market ($USD1.05M).
Compensation vs Earnings: Gene's compensation has been consistent with company performance over the past year.
CEO
Gene Kinney (57 yo)
Dr. Gene G. Kinney, Ph D., is Chairman of the Board of Libra Therapeutics, Inc. Dr. Kinney has been the Chief Executive Officer and President of Prothena Corporation plc since September 26, 2016 and Octobe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10yrs | US$5.90m | 0.30% € 1.2m | |
| Chief Financial Officer | 13.5yrs | US$2.66m | 0.19% € 751.6k | |
| Chief Operating Officer | 4.9yrs | US$2.81m | 0.25% € 1.0m | |
| Chief Scientific Officer | 9.3yrs | US$2.41m | 0.17% € 657.3k | |
| Chief Development Officer | 2yrs | US$2.42m | 0.079% € 315.0k | |
| Chief Accounting Officer & Controller | 13.3yrs | no data | 0.049% € 193.3k | |
| Vice President of Investor Relations | no data | no data | no data | |
| General Counsel & Corporate Secretary | less than a year | no data | 0.070% € 276.4k | |
| Sr. Director & Head of Exploratory Research | no data | no data | no data | |
| Chief Strategy Officer | less than a year | no data | 0.11% € 431.3k |
Experienced Management: 0PT's management team is seasoned and experienced (7.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10yrs | US$5.90m | 0.30% € 1.2m | |
| Independent Director | 13.8yrs | US$175.83k | 0.0024% € 9.4k | |
| Independent Chairman | 2.6yrs | US$192.92k | 0% € 0 | |
| Independent Chair Emeritus | 21.3yrs | US$175.83k | 0.00047% € 1.9k | |
| Independent Director | 13.8yrs | US$183.33k | 0% € 0 | |
| Independent Director | 13.2yrs | US$172.33k | 0.0082% € 32.6k | |
| Independent Director | 3.3yrs | US$170.56k | 0% € 0 |
Experienced Board: 0PT's board of directors are seasoned and experienced ( 13.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 05:40 |
| End of Day Share Price | 2026/09/14 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Prothena Corporation plc is covered by 24 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | Barclays |
| Tazeen Ahmad | BofA Global Research |
| null null | BTIG |